Fmr LLC raised its holdings in shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Rating) by 1.7% during the second quarter, HoldingsChannel reports. The firm owned 5,846,060 shares of the biotechnology company’s stock after purchasing an additional 99,320 shares during the period. Fmr LLC owned about 0.06% of Atara Biotherapeutics worth $45,541,000 as of its most recent SEC filing.
A number of other institutional investors have also added to or reduced their stakes in the business. JPMorgan Chase & Co. increased its position in Atara Biotherapeutics by 8.2% during the 2nd quarter. JPMorgan Chase & Co. now owns 8,861,252 shares of the biotechnology company’s stock valued at $69,029,000 after purchasing an additional 671,353 shares during the period. State Street Corp increased its position in Atara Biotherapeutics by 45.1% during the 1st quarter. State Street Corp now owns 6,273,617 shares of the biotechnology company’s stock valued at $58,282,000 after purchasing an additional 1,949,418 shares during the period. Wasatch Advisors Inc. increased its position in Atara Biotherapeutics by 88.8% during the 1st quarter. Wasatch Advisors Inc. now owns 3,823,588 shares of the biotechnology company’s stock valued at $35,521,000 after purchasing an additional 1,798,072 shares during the period. Goldman Sachs Group Inc. increased its position in Atara Biotherapeutics by 41.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 3,638,106 shares of the biotechnology company’s stock valued at $33,798,000 after purchasing an additional 1,073,579 shares during the period. Finally, Eminence Capital LP increased its position in Atara Biotherapeutics by 19.8% during the 1st quarter. Eminence Capital LP now owns 1,367,710 shares of the biotechnology company’s stock valued at $12,706,000 after purchasing an additional 226,253 shares during the period.
Atara Biotherapeutics Stock Up 4.0 %
ATRA stock opened at $4.66 on Thursday. The firm has a 50 day moving average of $4.34 and a 200 day moving average of $4.73. The stock has a market capitalization of $442.14 million, a PE ratio of -1.89 and a beta of 1.00. Atara Biotherapeutics, Inc. has a 52 week low of $2.83 and a 52 week high of $18.02.
Insider Buying and Selling
In related news, CFO Utpal Koppikar sold 6,255 shares of Atara Biotherapeutics stock in a transaction that occurred on Wednesday, November 16th. The shares were sold at an average price of $4.49, for a total value of $28,084.95. Following the completion of the sale, the chief financial officer now directly owns 191,334 shares in the company, valued at approximately $859,089.66. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CFO Utpal Koppikar sold 6,255 shares of Atara Biotherapeutics stock in a transaction that occurred on Wednesday, November 16th. The shares were sold at an average price of $4.49, for a total value of $28,084.95. Following the completion of the sale, the chief financial officer now directly owns 191,334 shares in the company, valued at approximately $859,089.66. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Pascal Touchon sold 15,591 shares of Atara Biotherapeutics stock in a transaction that occurred on Wednesday, November 16th. The stock was sold at an average price of $4.49, for a total transaction of $70,003.59. Following the completion of the sale, the chief executive officer now owns 441,696 shares of the company’s stock, valued at $1,983,215.04. The disclosure for this sale can be found here. Insiders sold 29,800 shares of company stock worth $133,802 in the last three months. Corporate insiders own 4.00% of the company’s stock.
Analyst Ratings Changes
A number of research analysts have recently issued reports on ATRA shares. Mizuho cut their price objective on shares of Atara Biotherapeutics from $39.00 to $31.00 and set a “buy” rating on the stock in a research report on Tuesday, August 16th. StockNews.com started coverage on shares of Atara Biotherapeutics in a research report on Wednesday, October 12th. They issued a “hold” rating on the stock. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $18.71.
Atara Biotherapeutics Company Profile
(Get Rating)
Atara Biotherapeutics, Inc is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. also delivers off-the-shelf treatments to patients with high unmet medical need.
Recommended Stories
Want to see what other hedge funds are holding ATRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Rating).
Receive News & Ratings for Atara Biotherapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Atara Biotherapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.
